Skip to main content

and
Your search also matched 2 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Fortschritte in der Immuncheckpoint-Inhibitor-Therapie beim Bronchialkarzinom

Include preview-only content
  1. Article

    Open Access

    Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

    Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam in BMC Cancer (2023)

  2. Article

    Open Access

    Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial

    Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCL...

    Farastuk Bozorgmehr, Petros Christopoulos, Inn Chung, Jelena Cvetkovic in BMC Cancer (2022)

  3. Article

    Open Access

    Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenoty**: study protocol of the ABP trial

    Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second...

    Petros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, Inn Chung in BMC Cancer (2021)

  4. Article

    Open Access

    Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

    Non-small cell lung cancer is the most common cause of cancer death worldwide, highlighting the need for novel therapeutic concepts. In particular, there is still a lack of treatment strategies for the group o...

    Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam in BMC Cancer (2020)

  5. Article

    Open Access

    TelNet - a database for human and yeast genes involved in telomere maintenance

    The ends of linear chromosomes, the telomeres, comprise repetitive DNA sequences in complex with proteins that protects them from being processed by the DNA repair machinery. Cancer cells need to counteract th...

    Delia M. Braun, Inn Chung, Nick Kepper, Katharina I. Deeg, Karsten Rippe in BMC Genetics (2018)

  6. Article

    Open Access

    Integrative genomic and transcriptomic analysis of leiomyosarcoma

    Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknow...

    Priya Chudasama, Sadaf S. Mughal, Mathijs A. Sanders in Nature Communications (2018)